Bilang bahagi ng emergency grant aid nito sa mga bansang malaki ang problemang kinahaharap ngayon bunsod ng pandemya, nagpadala ang Japan ng Avigan tablets para sa 100 COVID-19 patients sa Pilipinas.
Ads
Ayon statement mula sa Japanese Embassy sa Manila, nakarating na sa Department of Health (DOH) ang Japan-made anti-flu drug na Avigan; kamakailan lamang ay nakapukaw ng interes ng maraming bansa dahil sa potensyal nito na pumigil ng viral replication, kahit pa ang bisa nito kontra sa COVID-19 ay kasalukuyan pang tinitingnan.
“The Government of Japan delivered Avigan tablets for 100 patients to the Philippine Department of Health on August 6, 2020 as part of its emergency grant aid to countries severely affected by COVID-19,” saad ng embahada.
Ads
Sponsored Links
“Japan-made anti-flu drug Avigan has drawn interest from many countries for its potential to prevent viral replication, even as its effectiveness against the novel coronavirus is yet to be established," pagpapatuloy nito.
Avigan: Clinical Research
Bilang tugon sa mga request ng mula sa international community, nakipag-ugnayan ang Japan sa iba't ibang bansa--kabilang na ang Pilipinas--upang mas mapalawak pa ang pananaliksik nito na may kinalaman sa paggamit ng Avigan bilang lunas sa mga nakahahawang sakit.
“In response to the requests received from the international community, Japan has formed close cooperation with several countries, including the Philippines, to expand clinical research on Avigan as treatment for this infectious disease,” saad ng statement.
“Each recipient government has acknowledged of Avigan’s proper usage and prescription in view of its known adverse side effects,” dagdag pa nito.
Umaasa raw ang Japan na makatutulong ang pakikipag-isa nito sa Pilipinas sa layuning makatuklas ng paraan upang mapahinto na ang COVID-19 pandemic.
“Japan hopes that this ongoing cooperation with the Philippines would further contribute to the advancement of clinical research to contain the COVID-19 pandemic,” wika nito.
READ MORE:
©2020 THOUGHTSKOTO
No comments:
Post a Comment